NEW BRUNSWICK, N.J., June 27, 2011 /PRNewswire/ -- Recent findings published in the scientific journal Leukemia Research ( http://www.sciencedirect.com/science/article/pii/S0145212611002505 ), showed that when combined with standard anti-leukemia agents, the biological activity of LeukotheraTM, a drug candidate under development by Actinobac Biomed, Inc., showed synergistic anti-leukemia effects.
The outcome of these in vitro experiments demonstrated that combining LeukotheraTM with such widely employed drugs as etoposide, mitoxantrone, daunorubicin, busulfan and imatinib killed leukemia cells much more effectively than when the agents were used alone. LeukotheraTM is a natural biologic agent that specifically targets malignant and/or inflammatory white blood cells involved in disease.
Dr. Scott Kachlany, founder of Actinobac Biomed, explained. "Drug combination therapies for cancer are now frequently considered by oncologists due to their many advantages, which include the possibility of reducing doses of toxic chemotherapeutic agents and a lower chance of developing drug resistance," he said. "The biological mechanism of LeukotheraTM differs from that of other cancer drugs so including it to blood cancer treatment protocols may be a highly effective strategy."
Actinobac Biomed, Inc. was founded in 2009 with financial backing from Foundation Venture Capital Group, LLC, to develop commercial products based upon technology developed at the University of Medicine and Dentistry of New Jersey. The company has exclusively licensed the rights to develop LeukotheraTM as a therapeutic agent for the treatment of hematologic malignancies, autoimmune and inflammatory diseases and HIV infection.
"We provided early seed funding to Actinobac because we are convinced that